SML2655
Reparixin
≥98% (HPLC)
别名:
αR-methyl-4-(2-methylpropyl)-N-(methylsulfonyl)-benzeneacetamide, (R)-(-)-N-2-[(4-Isobutylphenyl)propionyl]methanesulfonamide, DF 1681Y, Repertaxin
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
经验公式（希尔记法）:
C14H21NO3S
化学文摘社编号:
分子量:
283.39
UNSPSC Code:
51111800
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D -80 to -90°, c = 1.0 in ethanol
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
SMILES string
[S](=O)(=O)(NC(=O)C(C)c1ccc(cc1)CC(C)C)C
InChI
1S/C14H21NO3S/c1-10(2)9-12-5-7-13(8-6-12)11(3)14(16)15-19(4,17)18/h5-8,10-11H,9H2,1-4H3,(H,15,16)
InChI key
KQDRVXQXKZXMHP-UHFFFAOYSA-N
Biochem/physiol Actions
Noncompetitive allosteric inhibitor of the inflammatory CXCL8 (IL-8) chemokine receptors CXCR1 and CXCR2
Reparixin is a noncompetitive allosteric inhibitor of the inflammatory CXCL8 (IL-8) chemokine receptors CXCR1 and CXCR2 with IC50 values of 1 nM for CXCR1 and 100 nM for CXCR2. It is believed to prevent receptor signaling by locking CXCR1/R2 in an inactive conformation. Reparixin has been studied to prevent ischaemia-reperfusion injury and inflammation and is clinical trials for triple negative breast cancer and to prevent injury occurring after pancreatic islet transplantation.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable